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Laminin receptor()-Epigallocatechin-3-O-gallate (EGCG), a polyphenol in green tea, induces apoptosis in acute mye-
loid leukemia (AML) cells without affecting normal cells. In this study, we observed that cGMP acts
as a cell death mediator of the EGCG-induced anti-AML effect through acid sphingomyelinase acti-
vation. EGCG activated the Akt/eNOS axis, a well-known mechanism in vascular cGMP upregulation.
We also observed that a major cGMP negative regulator, phosphodiesterase 5, was overexpressed in
AML cells, and PDE5 inhibitor, an anti-erectile dysfunction drug, synergistically enhanced the anti-
AML effect of EGCG. This combination regimen killed AML cells via overexpressed 67-kDa laminin
receptors.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Acute myeloid leukemia (AML) is a hematopoietic malignancy
that is characterized by increased myeloid cells in the bone mar-
row, with arrested maturation [1]. The widely used combination
of daunorubicin and cytarabine results in complete remission in
50–75% of patients with AML [2]. However, the outcome for many
patients remains poor because of the development of chemother-
apy resistance [3], or drug toxicity in those that remain sensitive
to standard chemotherapy [4]. These problems highlight the need
for a novel strategy to treat AML.
Green tea (Camellia sinensis) is one of the most widely con-
sumed beverages in the world. An epidemic study on a cohort of
approximately 42000 individuals showed that green tea intakereduced the risk of hematological malignancies [5]. A phase II clin-
ical trial demonstrated that green tea extract intake partially re-
duced both the absolute lymphocyte count and palpable
adenopathy in patients with chronic lymphocytic leukemia [6].
Importantly, green tea polyphenols are well tolerated by patients
in clinical studies [6,7], and green tea extract has been approved
by the US Food and Drug Administration as the ﬁrst botanical drug.
The 67-kDa laminin receptor (67LR) is overexpressed in various
types of cancer, including multiple myeloma [8] and AML [9].
Overexpressed 67LR is involved in metastasis [10], which indicates
that 67LR has a vital role in cancer progression.
Several studies have demonstrated that ()-epigallocatechin-
3-O-gallate (EGCG) plays a pivotal role in the anticancer effects
of green tea polyphenols [11]. 67LR has been identiﬁed as an
EGCG receptor [12–14], and its overexpression in AML mediates
EGCG-induced apoptosis [9]. However, little is known about the
molecular mechanisms of EGCG-induced, AML-speciﬁc cell death.
Also, the concentration of plasma EGCG elicits limited killing
activity.
In this study, we demonstrated that the cGMP/acid sphingomy-
elinase (ASM) axis had a central role in the anti-AML effect of
EGCG. We also observed that phosphodiesterase (PDE) 5, a
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logical inhibition of PDE5 using vardenaﬁl (VDN), an anti-erectile
dysfunction drug, potentiated the anti-AML effect of EGCG without
affecting normal cells. Importantly, the anti-AML effect from this
combination was attenuated by anti-67LR antibody pretreatment
and ASM inhibition. Collectively, PDE5 inhibition potentiated the
anti-AML effect of EGCG, with selective toxicity.
2. Materials and methods
2.1. Materials and patient samples
Primary AML samples were obtained from DV Biologics (Costa
Mesa, CA) after informed consent was obtained. Fetal calf serum
(FCS) was obtained from Biowest (Nuaillé, France). Penicillin and
streptomycin were purchased from Meiji (Tokyo, Japan), and RPMI
1640 was from Nissui Pharmaceutical Co. Ltd. (Tokyo, Japan).
EGCG, sodium nitroprusside dihydrate (SNP) and desipramine
were purchased from Sigma–Aldrich (St. Louis, MO, USA). Rolipram
and 8-met-3-isobutyl-1-methylxanthine (8-Met IBMX) were pur-
chased from Calbiochem (La Jolla, CA). Vardenaﬁl was provided
by TRC (Toronto, Canada). Anti-67LR and anti-PDE5 antibodies
were obtained from Abcam (Vienna, Austria). Anti-eNOS antibody
was purchased from Cell Signaling Technology (Danvers, MA) and
anti-p-eNOS (Ser1177) was purchased from BD (San Jose, CA).
Anti-ASM antibody was provided by Santa Cruz Biotechnology
(Santa Cruz, CA). Anti-b-actin antibody was obtained from Sigma
(St. Louis, MO, USA).
2.2. Cell cultures
Human AML cell line HL60 was obtained from Riken Cell Bank
(Tsukuba, Japan). Cells were maintained in exponential phase in
RPMI 1640 supplemented with 10% (v/v) FCS, 100 U/ml penicillin,
and 100 lg/ml streptomycin at 37 C in 5% CO2 and 100% humidity.Fig. 1. 67LR and ASM play a pivotal role in the anti-AML effect of green tea polypheno
measured using the trypan blue method. (B and C) Sensitivity of HL60 cells to EGCG (10 l
3 h and ASM activity was evaluated. (E) Cells were precultured with or without 5 lM ASM
blue method. (F and G) Sensitivity of HL60 cells to EGCG (10 lM for 96 h) after ASM knpLKO.1 vectors encoding scrambled control shRNA or shRNAs
targeting 67LR and ASM were purchased from Sigma–Aldrich (St.
Louis, MO, USA).
2.3. Western blot analysis
Cells (1  106 cells/dish) were seeded onto a 100-mm tissue
culture dish and treated with various agents as indicated in the ﬁg-
ure legends. After treatment, cells were centrifuged, washed with
cold PBS, and lysed in lysis buffer. Western blotting was performed
as previously described [15]. Band intensities were scanned and
quantiﬁed using Image J software.
2.4. In vitro assays and ﬂow cytometry
The effects of EGCG and/or the indicated compounds on viable
cell numbers were examined using the trypan blue method [13].
The apoptotic effect was determined by FACSCalibur (Becton Dick-
inson, Franklin Lakes, NJ, USA) using Annexin V and Alexa Fluor
488 (Invitrogen, Grand Island, NY, USA). Akt kinase activity was
measured using a K-LISA Akt Activity Kit (Merck Millipore, Bille-
rica, MA, USA) and evaluated using an Envision plate reader (Per-
kin–Elmer, Montreal, Canada). Intercellular cGMP levels were
detected using an AlphaScreen cGMP Assay Kit and evaluated using
EnSpire Alpha (Perkin–Elmer). The production of nitric oxide (NO)
in cultured cells was assayed using 4,5-diaminoﬂuorescein diace-
tate (DAF-2DA; Sekisui Medical, Tokyo, Japan). ASM activity was
measured using BODIPY-C12 (Invitrogen).
2.5. Statistical analyses
All values are expressed as means ± S.E.M. Values are the mean
of at least three separate experiments in each group. One-way AN-
OVA followed by Tukey’s test was used for statistical comparisons.
A value of P < 0.05 was considered statistically signiﬁcant. Isobolo-l EGCG. (A) HL60 cells were treated with EGCG for 96 h. Viable cell numbers were
M for 96 h) after 67LR knockdown. (D) Cells were treated with 5 or 10 lM EGCG for
inhibitor desipramine for 3 h. Viable cell numbers were measured using the trypan
ockdown. Data are the mean ± S.E.M. (n = 3). ⁄⁄P < 0.01, ⁄⁄⁄ P < 0.001.
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3. Results
3.1. 67LR and ASM play a pivotal role in the anti-AML effect of green
tea polyphenol EGCG
The cytotoxicity of EGCG was evaluated in human AML cell line
HL60. EGCG inhibited cell growth in a dose-dependent manner
(Fig. 1A). The 50% inhibitory concentration (IC50) of EGCG was
21 lM. Previous studies have reported that overexpressed 67LR
in AML might be associated with the anti-AML effect of EGCG [9].
To conﬁrm the role of 67LR in the anti-AML effect of EGCG, we
transfected HL60 cells with a lentivirus encoding scramble shRNA
or shRNA against 67LR (Fig. 1B). Silencing of 67LR abrogated the
anti-AML effect of EGCG (Fig. 1C). 67LR is involved in Sindbis virus
infection, and Sindbis virus induces cell death through ASM activa-
tion [17]. Therefore, we investigated the role of ASM in the anti-
AML effect of EGCG. We treated HL60 cells with EGCG for 3 h
and evaluated ASM activity (Fig. 1D). EGCG activated ASM activity
in the AML cells. To assess the role of ASM in EGCG-induced cell
death, we examined the effect of the ASM inhibitor desipramine
(Fig. 1E). Desipramine signiﬁcantly abrogated the anti-AML effect
elicited by EGCG. To determine the involvement of ASM in the
anti-AML effect of EGCG, HL60 cells were transfected with a lenti-
virus encoding scrambled control shRNA or shRNA against ASM
(Fig. 1F). Silencing of ASM canceled the anti-AML effect of EGCG
(Fig. 1F and G).
3.2. NO/cGMP induced ASM activation in AML cells
EGCG relaxes the isolated bovine ophthalmic artery through the
NO/cGMP signaling pathway [18]. However, little is known about
the effect of EGCG on cGMP levels in AML cells. As shown in
Fig. 2A, EGCG increased the intercellular cGMP levels in AML cells.
In addition, BAY 41-2272, a soluble guanylate cyclase (sGC) stimu-
lator and inducer of cGMP synthesis, increased ASM activity
(Fig. 2B) and reduced the number of viable cells (Fig. 2C).Fig. 2. NO/cGMP induced ASM activation in AML cells. (A) HL60 cells were treated with E
Bay 41–2272 (2.5 lM) for 2 h. ASM activity was evaluated by TLC analysis. (C) HL60 ce
measured. (D) HL60 cells were treated with EGCG for 1 h and NO production was evalu
activity was evaluated. (F) HL60 cells were cultured with EGCG for 1 h. Phosphorylation
treated with EGCG for 1 h and Akt activity was evaluated. Data are the mean S.E.M. (n =We then investigated the role of NO, a crucial signal in the
cGMP pathway, in the effect of EGCG. EGCG induced NO production
in AML cells (Fig. 2D), and SNP, an NO donor, upregulated ASM
activity (Fig. 2E).
NO is synthesized from L-arginine by several isoforms of NO
synthase (NOS). The isoforms of NOS are divided into inducible
NOS and constitutive NOS (cNOS). cNOS is further classiﬁed as neu-
ronal NOS and endothelial NOS (eNOS). As shown in Fig. 2F, EGCG
increased phosphorylation of eNOS at Ser1177, a surrogate marker
for eNOS activation. Akt is involved in the activation of eNOS
through Ser 1177 phosphorylation [19]. To investigate the effect
of EGCG on Akt activity, HL60 cells were treated with EGCG for
1 h. EGCG increased the kinase activity of Akt in HL60 cells
(Fig. 2G).
These results suggest that the cGMP/ASM axis plays a central
role in EGCG-induced cell death in AML cells.
3.3. PDE5 inhibitor synergistically potentiated the anti-AML effect of
EGCG without affecting normal cells
Our ﬁndings suggest that the cGMP/ASM axis is the initial
mechanism in the anti-AML effect of EGCG. However, the effect
of EGCG at a physiological concentration (5 lM) was limited in
AML cells (Fig. 1A).
Eleven families of PDE degrade cAMP and cGMP by hydrolyzing
the 30,50-phosphodiester bond. Several PDE selective inhibitors are
used therapeutically [20–22]. PDE5 inhibitor vardenaﬁl (VDN),
which is clinically used for treating erectile dysfunction, signiﬁ-
cantly potentiated the anti-AML effect of EGCG on HL60 cells
(Fig. 3A). In contrast, the other PDE inhibitors, including PDE1
inhibitor (8-Met-IBMX) and PDE 4 inhibitor (rolipram), did not af-
fect the anti-AML effect of EGCG.
The isobologram plot is an accurate method for evaluating syn-
ergy based on the dose–response relationship of individual drugs
[23]. The IC50 of EGCG was 21 lM (Fig. 1A), and that of VDN
was 77 lM (Fig. 3B). A straight line was described by plotting
the IC50 dose of EGCG (Fig. 1A) and VDN (Fig. 3B) on the x and y
axes. To determine whether EGCG and VDN were simply additive
or synergistic, we evaluated the IC50 of EGCG with or withoutGCG for 3 h and cGMP was evaluated. (B) HL60 cells were treated with sGC activator
lls were treated with Bay 41–2272 (2.5 lM) for 96 h and viable cell numbers were
ated by DAF2DA. (E) HL60 cells were treated with NO donor SNP for 2 h and ASM
of eNOS at Ser1177 was measured by immunoblotting (n = 4). (G) HL60 cells were
3). ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001.
Fig. 3. PDE5 inhibitor synergistically potentiated the anti-AML effect of EGCG without affecting normal cells. (A) HL60 cells were cultured with or without PDE inhibitors,
including PDE1 inhibitor (8-Met-IBMX, 20 lM), PDE4 inhibitor (rolipram, 10 lM), or PDE5 inhibitor (VDN, 5 lM) for 3 h in the presence or absence of 5 lM EGCG for 96 h.
Viable cell numbers were measured. Data are the mean S.E.M. (n = 3). (B) HL60 cells were treated with VDN for 96 h and viable cell numbers were measured. (C) HL60 cells
were cultured with or without VDN (5 lM) and/or EGCG for 96 h, and viable cell numbers were measured. (D) Isobologram analysis revealed the combinations of EGCG and
VDN. (E) Patient AML cells and normal PBMCs were treated with VDN (5 lM) with or without EGCG (5 lM) for 96 h. Viable cell numbers were measured. Data are the mean
S.E.M. (n = 3). ⁄⁄⁄P < 0.001.
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fect of EGCG with an IC50 of 2.4 lM (Fig. 3C) compared with EGCG
alone (IC50 = 21 lM). Isobologram analysis of growth-inhibition
curves revealed that combination of EGCG and VDNwas not simply
additive but synergistic (Fig. 3D). Moreover, VDN potentiated the
anti-AML effect of EGCG on primary AML cells without affecting
normal peripheral blood mononuclear cells (PBMCs) (Fig. 3E). Col-
lectively, VDN synergistically potentiated the anti-AML effect of
EGCG without affecting normal cells.
3.4. Combined EGCG/VDN induced apoptotic death in AML cells via
67LR
VDN potentiated EGCG-induced apoptotic cell death (Fig. 4A).
However, little is known about the expression of PDE5 in AML
compared with its normal cell counterparts. Western blot analysis
showed that the levels of PDE5 were elevated in patient AML cells
and HL60 cells (Fig. 4B). Previous studies suggest that overexpres-
sion of 67LR in cancer cells contributes to the selective toxicity of
EGCG [9]. Importantly, the AML-killing effect of EGCG/VDN in com-
bination was completely attenuated when the cells were pre-
treated with anti-67LR antibodies (Fig. 4C). Desipramine, an ASM
inhibitor, also attenuated the AML killing effect of EGCG/VDN
(Fig. 4D).
4. Discussion
67LR is a surface protein and oncofetal antigen [24], which is
overexpressed on the surface of a variety of cancer cells [8,9]. Over-
expression of 67LR in AML mediates EGCG-induced, AML-speciﬁc
cell death. However, little is known about the early molecular
events after the binding of EGCG to 67LR. In the present study,we found that the cGMP/ASM axis plays a critical role in EGCG-in-
duced, AML-speciﬁc cell death.
The roles of cGMP in cardiovascular disease, vascular homeosta-
sis, and physiological and sexual dysfunction have been thoroughly
researched [25]. However, little is known about the role of cGMP in
leukemia. In the present study, we observed that cGMP acts as a
cell death mediator in AML cells.
The EGCG-induced eNOS/cGMP axis plays a pivotal role in
EGCG-induced AML cell death. However, the effect of EGCG at a
physiological concentration (5 lM) was limited in AML cells. Ele-
ven families of PDE degrade cAMP and cGMP by hydrolyzing the
30,50-phosphodiester bond. Each PDE has unique regulatory charac-
teristics and distribution, therefore, they could be ideal drug tar-
gets. Several selective PDE inhibitors are used clinically for
treating erectile dysfunction [20], intermittent claudication [21],
and asthma [22]. Several studies have reported overexpression of
speciﬁc PDEs in cancer cells, including melanoma (PDE4) [26],
plasmacytoma (PDE5) [14], and chronic lymphocytic leukemia
(PDE7) [27]. In our study, we observed that a cGMP negative regu-
lator, PDE5, was overexpressed in AML cells. Also, the PDE5 inhib-
itor, VDN, signiﬁcantly enhanced the anti-AML effect of EGCG at
plasma levels observed in clinical trials [7,8].
The current treatment of AML is high-dose cytarabine plus
anthracycline/anthracenedione. However, this treatment can be-
come ineffective because of increased drug resistance [3]. In some
cases, chemotherapy has to be discontinued because of adverse ef-
fects, which include bone marrow depression induced by indis-
criminate killing of cells.
At present, new drugs with different mechanisms and highly
selective toxicity are required. Our results are promising because
PDE5 inhibitors are safe drugs and are FDA approved for chronic
use. We observed that VDN potentiated the anti-AML effect of
Fig. 4. Combined EGCG/VDN induced apoptotic cell death in AML cells via 67LR. (A) HL60 cells were cultured with or without VDN (5 lM) and/or EGCG (5 lM) for 96 h.
Apoptotic cells were stained with Annexin V and Alexa Fluor 488. Apoptotic cells were evaluated using ﬂow cytometry. (B) Protein levels of PDE5 were evaluated in normal
PBMCs, AML patient cells, and HL60 cells. (C) HL60 cells were pretreated with anti-67LR antibodies or control IgM antibodies and then treated with EGCG (5 lM) and VDN
(5 lM) for 96 h. Apoptotic cells were stained with Annexin V and Alexa Fluor 488, and evaluated using ﬂow cytometry. (D) HL60 cells were pretreated with desipramine and
then treated with EGCG (5 lM) and VDN (5 lM) for 96 h. Apoptotic cells were stained with Annexin V and Alexa Fluor 488, and evaluated using ﬂow cytometry. Data are the
mean ± S.E.M. (n = 3). ⁄⁄⁄P < 0.001.
3056 M. Kumazoe et al. / FEBS Letters 587 (2013) 3052–3057EGCG without increasing the cytotoxicity of the normal cells. This
combination remains AML-overexpressed 67LR dependent.
In conclusion, PDE5 inhibitor potentiated the anti-AML effect of
EGCG with selective toxicity. EGCG/VDN in combination could pro-
vide a novel strategy for AML chemotherapy.
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